SKA1 and neoplasm: Subgroup analysis by different clinical features revealed that high SKA1 expression was strongly associated with poor prognosis in LIHC cases stage III and IV LIHC (OS: P = .022, DSS: P = .007), M0 (OS and DSS: P < .001), T3 and T4 (OS: P = .038, DSS: P = .013), male (OS and DSS: P < .001), N0 (OS and DSS: P < .001), with tumor (OS and DSS: P < .001), as shown in Figure 8A–L.